Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.72 |
| ▸ | CA1 | P00915 | 8/20 | 0.72 |
| ▸ | CA2 | P00918 | 8/20 | 0.72 |
| ▸ | CA9 | Q16790 | 8/20 | 0.72 |
| ▸ | CA4 | P22748 | 7/20 | 0.72 |
| ▸ | CA6 | P23280 | 7/20 | 0.72 |
| ▸ | CA7 | P43166 | 7/20 | 0.72 |
| ▸ | CA13 | Q8N1Q1 | 7/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.72 |
| ▸ | CISD1 | Q9NZ45 | 7/20 | 0.72 |
| ▸ | CA3 | P07451 | 6/20 | 0.72 |
| ▸ | CA5A | P35218 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876194 | 0.86 | CISD1 (0.72) | CA12CA1CA2CA9CA4 | |
| SCHEMBL15076647 | 0.86 | CA1 (0.72) | CA12CA1CA2CA9CA4 | |
| SCHEMBL21844979 | 0.85 | CA1 (0.51) | CA12CA1CA2CA9CA4 | |
| SCHEMBL3856779 | 0.84 | CA12 (0.54) | CA12CA1CA2CA9CA4 | |
| SCHEMBL397474 | 0.84 | CA12 (0.54) | CA12CA1CA2CA9CA4 | |
| SCHEMBL31717970 | 0.84 | CA12 (1.00) | CA12CA1CA2CA9CA4 | |
| SCHEMBL574023 | 0.84 | CA12 (1.00) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1489054 | 0.84 | CA1 (0.55) | CA12CA1CA2CA9CA4 | |
| SCHEMBL8574555 | 0.83 | CA12 (0.53) | CA12CA1CA2CA9CA4 | |
| Hydrochloric Acid SCHEMBL11158505 | 0.82 | CA12 (0.96) | CA12CA1CA2CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11557793-B2 | Flexible all-solid-state lithium-ion secondary battery having gelable system containing lithium salt and ether compound, and preparation method thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-01-17 | — | — | US | disclosed |
| US-11545696-B2 | Gelable system and uses thereof in lithium-air batteries, organic supercapacitors or capacitor batteries | BEIJING NORMAL UNIVERSITY (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220184008-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2022-06-16 | — | — | US | disclosed |
| CN-114174259-A | Modulators of intracellular chloride concentration | 意大利学院科技基金会 | 2022-03-11 | — | — | CN | disclosed |
| EP-3947345-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020202072-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-10-08 | — | — | WO | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | UNIV ARIZONA STATE (US) | 2015-08-13 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1569931-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| WO-2004055011-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-4029787-A | Basically substituted 3-sulfamoylbenzoic acid derivatives and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | AQP1, AQP4, AQP3 | CA12 1649/4885CA1 1196/4885CA2 168/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | CA12 4519/4885CA1 4845/4885CA2 4605/4885 |
| US-20220184008-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | SLC6A1, SLC6A13, SLC6A11 | CA12 2754/4885CA1 667/4885CA2 165/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | CA12 810/4885CA1 695/4885CA2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.